Bank of New York Mellon Corp Has $1.39 Billion Position in Pfizer Inc. $PFE

Bank of New York Mellon Corp lifted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 7.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,879,546 shares of the biopharmaceutical company's stock after purchasing an additional 3,999,646 shares during the period. Bank of New York Mellon Corp owned 1.02% of Pfizer worth $1,393,739,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in PFE. Godfrey Financial Associates Inc. bought a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Keb Asset Management LLC bought a new stake in shares of Pfizer in the 2nd quarter valued at $26,000. HFM Investment Advisors LLC increased its stake in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 427 shares in the last quarter. Evolution Wealth Management Inc. lifted its position in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 566 shares during the period. Finally, Abound Financial LLC bought a new position in Pfizer during the fourth quarter worth $31,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer shares benefited from renewed enthusiasm for cancer vaccines after Merck and Moderna reported positive melanoma-trial results for their personalized mRNA vaccine and Keytruda combination. The news has encouraged investors to reassess Pfizer’s own cancer-vaccine ambitions and broader mRNA exposure. Pfizer Stock Rises Wednesday: What's Going On?
• Positive Sentiment: Pfizer’s obesity strategy remains a potential long-term catalyst. Investors are watching berobenatide, a possible monthly treatment intended to compete with leading GLP-1 drugs and help diversify revenue beyond legacy products. Pfizer's Obesity Push
• Positive Sentiment: Pfizer’s high dividend yield and recent share performance are attracting income-oriented investors. Recent filings also indicate substantial hedge-fund buying, while unusually heavy call-option activity points to improving speculative sentiment. Yield Hunters and Hedge-Fund Buying
• Neutral Sentiment: Pfizer completed a real-world study evaluating Ibrance in advanced breast cancer. The study’s completion could provide useful evidence for the product, but investors are awaiting the data and any commercial implications. Pfizer's Ibrance Study Update
• Negative Sentiment: Pfizer is settling thousands of Depo-Provera lawsuits alleging a link to intracranial meningiomas. While a settlement program may reduce litigation uncertainty, it also highlights potentially significant financial exposure and keeps legal risk overhanging the stock. Why Is Pfizer Settling Thousands of Legal Claims?
• Negative Sentiment: Investors remain focused on Pfizer’s patent cliff. New and acquired medicines may replace much of the revenue lost as older patents expire, but the transition leaves limited room for execution errors and raises concerns about longer-term growth. Pfizer Stock Is a Race Between New Drugs and Old Patents
• Negative Sentiment: Merck’s deeper investment in personalized cancer vaccines raises the competitive bar for Pfizer and could make it harder for Pfizer to establish a leading position in this emerging market. Merck Raises the Stakes for Pfizer's Cancer Vaccine Ambitions

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on PFE. Citigroup upped their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 29th. HSBC lowered Pfizer from a "buy" rating to a "hold" rating and decreased their target price for the company from $32.00 to $28.00 in a research report on Monday, July 6th. Wolfe Research reaffirmed an "underperform" rating and set a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. BMO Capital Markets cut their price target on Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, July 13th. Finally, Royal Bank Of Canada raised Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price objective for the company in a research note on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, Pfizer has a consensus rating of "Hold" and an average target price of $28.28.

Pfizer Stock Performance

Shares of PFE opened at $27.83 on Friday. The firm has a market capitalization of $158.62 billion, a P/E ratio of 36.62 and a beta of 0.34. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75. The stock has a 50 day moving average price of $25.27 and a two-hundred day moving average price of $26.24. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the company earned $0.78 earnings per share. The company's revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.2%. Pfizer's dividend payout ratio (DPR) is 226.32%.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source